NCT03232905 is a Phase 1 clinical trial of PF-06651600 in Healthy, sponsored by Pfizer.

Who is sponsoring NCT03232905?

NCT03232905 is sponsored by Pfizer.

What drugs are being tested in NCT03232905?

Interventions in NCT03232905: PF-06651600, Placebo.

Is NCT03232905 still recruiting?

NCT03232905 is currently completed. Last updated 6 December 2017.

Last reviewed 2017-12-06 · How we verify

NCT03232905

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety and Pharmacokinetic Study of PF-06651600 in Japanese Healthy Volunteers

Completed Phase 1 Last updated 6 December 2017

What this trial tests

Phase 1 trial testing PF-06651600 in Healthy in 6 participants. Completed in 22 November 2017.

Timeline

30 August 2017

Primary endpoint
27 October 2017

22 November 2017

Quick facts

Lead sponsor	Pfizer
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	6
Start date	30 August 2017
Primary completion	27 October 2017
Estimated completion	22 November 2017
Sites	1 location across Belgium

Drugs / interventions tested

PF-06651600 (pf-06651600) — full drug profile →
Placebo

Conditions studied

Healthy — all drugs for Healthy →

Sponsor

Pfizer — full company profile →

Who can join

Adults 18 to 55, any sex, with Healthy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a phase 1 study of PF-06651600. PF-06651600 is being developed for treatment of inflammatory bowel disease. The goal of the study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of PF-06651600 after multiple oral doses of PF-06651600 in Japanese healthy volunteers.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Evolution of Ritlecitinib Population Pharmacokinetic Models During Clinical Drug Development.
Wojciechowski J, S Purohit V, Huh Y, Banfield C, et al · · 2023 · cited 12× · PMID 37917289 · DOI 10.1007/s40262-023-01318-3
Leveraging Prior Healthy Participant Pharmacokinetic Data to Evaluate the Impact of Renal and Hepatic Impairment on Ritlecitinib Pharmacokinetics.
Purohit V, Huh Y, Wojciechowski J, Plotka A, et al · · 2023 · cited 9× · PMID 36977960 · DOI 10.1208/s12248-023-00792-8

Verify or expand the search:

Other trials of PF-06651600

Trials testing the same drug.

NCT05549934 — Ritlecitinib for Cicatricial Alopecia · Phase 2 · completed
NCT04634565 — PHARMACOKINETIC CHARACTERIZATION OF PF-06651600 IN CHINESE ADULT PARTICIPANTS · Phase 1 · completed
NCT04390776 — Bioequivalence Study of PF-06651600 Capsules Relative to Tablets and Estimation of Food Effect on Capsules. · Phase 1 · completed
NCT04517864 — PLACEBO-CONTROLLED SAFETY STUDY OF RITLECITINIB (PF-06651600) IN ADULTS WITH ALOPECIA AREATA · Phase 2 · terminated
NCT04413617 — TO ASSESS THE EFFICACY AND SAFETY OF PF-06650833, PF-06651600, AND TOFACITINIB ALONE AND IN COMBINATION IN PARTICIPANTS · Phase 2 · completed

Other recruiting trials for Healthy

Currently open trials in the same condition.

NCT06707207 — Predicting Future Errors During Skill Performance · recruiting
NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease. · NA · recruiting
NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects · NA · recruiting
NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity · Phase 1, PHASE2 · recruiting

Other Pfizer trials

Trials by the same sponsor.

NCT04982848 — Korea Post Marketing Surveillance (PMS) Study of Talzenna® · not yet recruiting
NCT06873191 — A Study to Learn More About Tukysa Once it is Out in the Korean Market · not yet recruiting
NCT07497854 — A Study to Learn About the Study Medicine NURTEC® ODT 75 mg After it is Released Into the Markets in Korea · not yet recruiting
NCT06507904 — A Study to Learn How Different Preparations of Osivelotor Taste and Enter the Blood With Food or Liquids or With an Anta · Phase 1 · not yet recruiting
NCT06864585 — A Study to Learn About the Study Medicine - Zavicefta in Patients With Sepsis or Loss of Kidney Function in Japan · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03232905 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Pfizer
Last refreshed: 6 December 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03232905.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing